此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

2014年3月31日 更新者:Bayer

Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphere® Inhalation Powder

Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)

研究概览

研究类型

介入性

注册 (实际的)

19

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Niedersachsen
      • Hannover、Niedersachsen、德国、30625

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 75年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients with COPD, 40 to 75 years of age
  • Diagnosis of COPD
  • Airway obstruction with a post-bronchodilator Forced Expiratory Volume (FEV1) of >/=30% and </=65% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of </=70%
  • Current or ex-smokers with a smoking history of more than 10 pack-years
  • Patients must be able to produce acceptable induced sputum samples (as defined in the Study Procedure Manual)
  • Normal body weight: Body Mass Index (BMI) between 19 and 35 kg/m2

Exclusion Criteria:

  • Significant respiratory disease other than COPD as bronchial asthma, Cystic fibrosis or clinically evident bronchiectasis
  • More than one COPD exacerbation within 12 months and within 8 weeks prior to screening
  • total blood eosinophil count >/=600/mm3
  • Thoracotomy with pulmonary resection
  • Regularly use of daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
  • Hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder
  • Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution
  • Patients with a history of severe allergies, non-allergic drug reactions, or multiple drug allergies
  • Concomitant use of medication which could interfere with the investigational drug. Before study drug administration a wash out period of more than 5 half lives has to be considered
  • Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with

    • fluoroquinolones
    • Oral beta-andrenergics, beta blockers
    • oral steroids
    • Methylxanthines: 24-hour washout of short-acting theophylline and 48-hour washout of long-acting theophylline prior to pre-study examination
    • Antihistamines, antileukotrienes prescribed for asthma
    • oral cromolyn sodium or oral nedocromil sodium

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:手臂 1
32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
实验性的:手臂 2
32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
安慰剂比较:手臂 3
Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Vital signs
大体时间:Within 28 days after first treatment
Within 28 days after first treatment
Electrocardiogram (ECG)
大体时间:Within 28 days after first treatment
Within 28 days after first treatment
Pulmonary function test
大体时间:Within 28 days after first treatment
Within 28 days after first treatment
Pulse-oximetry
大体时间:Within 12 days after first treatment
Within 12 days after first treatment

次要结果测量

结果测量
大体时间
Ciprofloxacin concentrations in blood
大体时间:Within 14 days after first treatment
Within 14 days after first treatment
Ciprofloxacin concentrations in urine
大体时间:Within 14 days after first treatment
Within 14 days after first treatment
Ciprofloxacin concentrations in sputum
大体时间:Within 14 days after first treatment
Within 14 days after first treatment
Ciprofloxacin concentrations in mouth fluid
大体时间:Within 7 days after first treatment
Within 7 days after first treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年8月1日

初级完成 (实际的)

2010年3月1日

研究完成 (实际的)

2010年3月1日

研究注册日期

首次提交

2009年8月17日

首先提交符合 QC 标准的

2009年8月17日

首次发布 (估计)

2009年8月18日

研究记录更新

最后更新发布 (估计)

2014年4月1日

上次提交的符合 QC 标准的更新

2014年3月31日

最后验证

2014年3月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Ciprofloxacin (PulmoSphere, BAYQ3939)的临床试验

3
订阅